Fabrazyme 35 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FKFU9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,438
Award facts
- Contract value 100% obligated
- $13,437.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,437.78 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 35 mg vials of Fabrazyme. The delivery order, issued on December 19, 2025, with an ultimate completion date of January 13, 2026, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that authorizes DLA to issue firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with the PPV-G GEN V contract representing a $499.999 billion ceiling value through December 31, 2036. The contractor's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with demonstrated performance across numerous delivery orders ranging from under $100 to over $115,000. As a small business contractor operating within the DLA's Medical Supply Chain division, DMS Pharmaceutical Group leverages its established expertise and broad pharmaceutical distribution capabilities to fulfill the specialized and recurring medical supply requirements of the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FKFU9?
SPE2DR26FKFU9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26FKFU9 worth?
The government has obligated $13,438 on SPE2DR26FKFU9.
Is contract SPE2DR26FKFU9 an order under another contract?
Yes. SPE2DR26FKFU9 is a delivery order under SPE2DR25D9362, an indefinite delivery contract.
Was contract SPE2DR26FKFU9 competed?
The extent of competition for SPE2DR26FKFU9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award